||Recombinant Human CCL21 (Accession # NP_002980 (6Ckine) & P78423 (Fractalkine Mucin-like Stalk)), fused with , was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.
||Measured by its ability to chemoattract 5-10 day cultured human peripheral blood lymphocytes (PBL).The ED50 for this effect is typically 0.5 - 1.5 µg/mL.Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CCR7.The ED50 for this effect is typically 25 - 100 ng/mL.
||Recombinant Human CCL21 has a calculated MW of 38.3 kDa. In SDS-PAGE migrates as 95-105 kDa, reducing conditions.
||>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).